LBA37 - A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung)

Proffered Paper Session
© Copyright 2022 European Society for Medical Oncology (ESMO). All rights reserved.
Meeting: ESMO Congress 2022
Presenter: Martin Schuler
Presentation Date: September 9, 2022
Abstract Number: LBA37

973MO - KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC

Mini Oral Session
© Copyright 2022 European Society for Medical Oncology (ESMO). All rights reserved.
Meeting: ESMO Congress 2022
Presenter: Marina Garassino
Presentation Date: September 11, 2022
Abstract Number: 973MO

What’s next? Emerging next-generation immunotherapy in lung cancer

Discussion Session
© Copyright 2022 European Society for Medical Oncology (ESMO). All rights reserved.
Meeting: ESMO Congress 2022
Presenter: Natasha Leighl
Presentation Date: September 12, 2022

Disclaimer

This content was selected by and is provided to you courtesy of Your Company.

© Copyright 2022 European Society for Medical Oncology (ESMO). All rights reserved.

This selection of Meeting presentations was made by Your Company and ESMO did not participate in the selection. This selection of presentations does not necessarily represent a balanced view or full discussion of any given subject. Any summaries or commentary appearing herein were not prepared or reviewed by ESMO. The ideas and opinions expressed herein do not necessarily reflect the views of ESMO or Springer Healthcare.

The mention of any company, product, service, or therapy in this collection of materials does not constitute an endorsement of any kind by ESMO. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Viewers are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify, among other matters, the dosage, method, and duration of administration, or contraindications. Viewers are also encouraged to contact the manufacturer with questions about the features or limitations of any products. ESMO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions.

Springer Healthcare

Site provided by Springer Healthcare Limited. Part of the Springer Nature Group.

Selected Presentations from the ESMO Congress 2022
(For Demo Purposes Only)

Content Available: Video | Slides

By accessing this collection you are agreeing to the following terms and conditions, and certifying that the content provided is for your personal use only.

  • The modification, adaptation, manipulation, transformation, translation or creation of derivative works based on the materials is prohibited
  • The user may not remove, obscure or modify any copyright or other notices or disclaimers included in the materials
  • The user may not transmit in any format the materials to other persons
  • Printing copies for distribution for any reason is strictly prohibited
  • The user will take all reasonable security measures necessary to prevent unauthorised duplication or unauthorised distribution of the materials
  • You accept Springer Healthcare’s Privacy Policy
Please note, this is for demo purposes only. Your data will not be collected.

© Copyright 2022 European Society for Medical Oncology (ESMO). All rights reserved.